[Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
The authors report pharmacokinetics and indications of rifaximin and the results of clinical studies. Rifaximin has a large antibacterial spectrum with a good therapeutic effect on both gram positive and gram negative aerob and anaerob bacteria. Practically there is no absorption (< 1%) following oral administration with a high concentration in gastrointestinal mucosa (8000 microg/g). No increase in absorption can be detected in intestinal damage caused by inflammatory bowel disease. The remarkable safety profile of rifaximin is due to its negligible quality of absorption. According to the clinical studies rifaximin could be an adequate therapeutic approach in all gastrointestinal diseases and interventions when antibacterial therapy is needed.
Gasztonyi
Beáta
B
Pécsi Tudományegyetem, Orvostudományi és Egészségtudományi Centrum, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika, Pécs.
Hunyady
Béla
B
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy; D013505:Digestive System Surgical Procedures / Q000009:adverse effects; D004238:Diverticulitis / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D006501:Hepatic Encephalopathy / Q000188:drug therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D007408:Intestinal Absorption; D011183:Postoperative Complications / Q000517:prevention & control; D012294:Rifamycins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D000078262:Rifaximin
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D005765:Gastrointestinal Agents; D012294:Rifamycins; D000078262:Rifaximin